Analyst Research Report Snapshot

Title:

Ranbaxy Laboratories Limited

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

18 Mar 2015

Pages:

52

Type:

AcrobatPDF

Companies referenced:

Available for Immediate Download
Summary:

Ranbaxy Laboratories Limited - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on Ranbaxy Laboratories Limited required for business and competitor intelligence needs - A study of the major internal and external factors affecting Ranbaxy Laboratories Limited in the form of a SWOT analysis - An in-depth view of the business model of Ranbaxy Laboratories Limited including a breakdown and examination of key business segments - Intelligence on Ranbaxy Laboratories Limited’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Ranbaxy Laboratories Limited, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Ranbaxy Laboratories Limited (Ranbaxy or 'the company'), a subsidiary of Daiichi Sankyo, is a leading generic pharmaceutical company in India. It is engaged in the production, distribution and marketing of generics, value-added and over-the-counter (OTC) products, anti-retroviral (ARV), active pharmaceuticals ingredients (API), and intermediates. The company operates in Asia Pacific, Americas, Europe, Middle East and Africa. It is headquartered in Gurgaon, India, and employed 11,784 people as of March 31, 2014. The company recorded revenues of INR132,684.8 million (approximately $2,255.6 million) during the 15-month period ended March 31, 2014. The operating profit of the company was INR6,851.5 million (approximately $116.4 million) and the net loss was INR10,852.5 million (approximately $184.5 million) during the 15-month period. Ranbaxy changed its financial year from January–December to April–March, and reported financial for the 15-month period ended March 31, 2014. Hence, the company’s financials for the 15-month period cannot be compared with the financials of FY2012. In April 2014, Ranbaxy and Sun Pharmaceutical Industries (Sun Pharma), an India-based leading generic manufacturer, entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all-stock transaction. Reasons to Purchase: - Gain understanding of Ranbaxy Laboratories Limited and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Ranbaxy Laboratories Limited as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Ranbaxy Laboratories Limited’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.